Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment

<p>Abstract</p> <p>Background</p> <p>Mutations within the tumor suppressor <it>TP53 </it>gene are one of the most common genetic alterations present at high frequency in human tumors and have been shown to be associated with resistance to radio-chemotherapy....

Full description

Bibliographic Details
Main Authors: Abolmaali Nasreddin D, Tokalov Sergey V
Format: Article
Language:English
Published: BMC 2010-02-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/10/57
_version_ 1819030371051765760
author Abolmaali Nasreddin D
Tokalov Sergey V
author_facet Abolmaali Nasreddin D
Tokalov Sergey V
author_sort Abolmaali Nasreddin D
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Mutations within the tumor suppressor <it>TP53 </it>gene are one of the most common genetic alterations present at high frequency in human tumors and have been shown to be associated with resistance to radio-chemotherapy. The lack of the wild type <it>TP53 </it>gene in cancer cells could be exploited for therapeutic advantage using a sequence of two antagonistic drugs. The aim of this study was to selectively kill p53 deficient cells (FaDu and H1299) by taxol and to protect p53 wild type cells (A549) by the prior administration of nutlin-3 in comparison to certain known anticancer drugs (5-fluorouracil, camptothecin, roscovitine).</p> <p>Methods</p> <p>Cytotoxic and cytostatic properties of 5-fluorouracil, camptothecin, roscovitine and nutlin-3 administrating alone or in combination with taxol were investigated in vitro by flow cytometry.</p> <p>Results</p> <p>It was found that nutlin-3 induced growth arrest and protected A549 cells from taxol. FaDu and H1299 cells responded to the same treatments with mitotic arrest and massive apoptosis. Other compounds (5-fluorouracil, camptothecin and roscovitine) revealed weaker selectivity and elevated toxicity in comparison to nutlin-3.</p> <p>Conclusions</p> <p>We propose a therapeutic strategy protecting normal cells from taxol while increasing apoptosis selectively in p53-deficient cells using nutlin-3.</p>
first_indexed 2024-12-21T06:29:05Z
format Article
id doaj.art-6ee044686b9541608188fd7f4aacc6ac
institution Directory Open Access Journal
issn 1471-2407
language English
last_indexed 2024-12-21T06:29:05Z
publishDate 2010-02-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj.art-6ee044686b9541608188fd7f4aacc6ac2022-12-21T19:13:02ZengBMCBMC Cancer1471-24072010-02-011015710.1186/1471-2407-10-57Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatmentAbolmaali Nasreddin DTokalov Sergey V<p>Abstract</p> <p>Background</p> <p>Mutations within the tumor suppressor <it>TP53 </it>gene are one of the most common genetic alterations present at high frequency in human tumors and have been shown to be associated with resistance to radio-chemotherapy. The lack of the wild type <it>TP53 </it>gene in cancer cells could be exploited for therapeutic advantage using a sequence of two antagonistic drugs. The aim of this study was to selectively kill p53 deficient cells (FaDu and H1299) by taxol and to protect p53 wild type cells (A549) by the prior administration of nutlin-3 in comparison to certain known anticancer drugs (5-fluorouracil, camptothecin, roscovitine).</p> <p>Methods</p> <p>Cytotoxic and cytostatic properties of 5-fluorouracil, camptothecin, roscovitine and nutlin-3 administrating alone or in combination with taxol were investigated in vitro by flow cytometry.</p> <p>Results</p> <p>It was found that nutlin-3 induced growth arrest and protected A549 cells from taxol. FaDu and H1299 cells responded to the same treatments with mitotic arrest and massive apoptosis. Other compounds (5-fluorouracil, camptothecin and roscovitine) revealed weaker selectivity and elevated toxicity in comparison to nutlin-3.</p> <p>Conclusions</p> <p>We propose a therapeutic strategy protecting normal cells from taxol while increasing apoptosis selectively in p53-deficient cells using nutlin-3.</p>http://www.biomedcentral.com/1471-2407/10/57
spellingShingle Abolmaali Nasreddin D
Tokalov Sergey V
Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment
BMC Cancer
title Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment
title_full Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment
title_fullStr Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment
title_full_unstemmed Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment
title_short Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment
title_sort protection of p53 wild type cells from taxol by nutlin 3 in the combined lung cancer treatment
url http://www.biomedcentral.com/1471-2407/10/57
work_keys_str_mv AT abolmaalinasreddind protectionofp53wildtypecellsfromtaxolbynutlin3inthecombinedlungcancertreatment
AT tokalovsergeyv protectionofp53wildtypecellsfromtaxolbynutlin3inthecombinedlungcancertreatment